Furthermore, targeted delivery of the gene delivery system expressing CCR7 antagonistic proteins to the tumour site significantly inhibited CCL21/CCR7-mediated tumour cell lymphatic migration by blocking the binding of CCL21 to CCR7 in 4T1 and B16F10 30. This evidence concerns the gene CCR7 and neoplasm.